Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Meeting Abstract

  

Authors:	Sikov, W. M.; Berry, D. A.; Perou, C. M.; Singh, B.; Cirrincione, C.; Tolaney, S.; Kuzma, C. S.; Pluard, T. J.; Somlo, G.; Port, E.; Golshan, M.; Bellon, J. R.; Collyar, D.; Hahn, O. M.; Carey, L. A.; Hudis, C.; Winer, E. P.
Abstract Title:	Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Meeting Title:	36th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	73
Issue:	24 Suppl.
Meeting Dates:	2013 Dec 10-14
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2013-12-15
Language:	English
ACCESSION:	WOS:000209496903129
DOI:	10.1158/0008-5472.sabcs13-s5-01
PROVIDER:	wos
Notes:	Meeting Abstract: S5-01 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/99261